XORTX Therapeutics Inc
XRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$590.4K
Close$
$3.11
46.2% upside
Current Fair Value
46.2% upsideUndervalued by 46.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $590,397.00 |
|---|---|
| Enterprise Value | $354,404.00 |
| Dividend Yield | $0.30 (-) |
| Earnings per Share | $-14.2 |
| Beta | 0.17 |
| Outstanding Shares | 13,924 |
Return
| Return on Equity | -231.35% |
|---|---|
| Return on Assets | -138.48% |
| Return on Invested Capital | -245.86% |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | -1.31 |
| Price to Sales | - |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.07%▼ 3.25% |
|---|---|
| Total Invested | $19▼ 99.98% |
| Investors Holding | 1▼ 5.00% |
ESG Score
No data
About XORTX Therapeutics Inc
CEO: Allen Davidoff